FDA warned South Korea's MJS Medicals for selling unapproved, misbranded botulinum toxin ("Innotox") to U.S. consumers online.
What happened
FDA reviewed the website www.mjsmedicals.com and found it offering injectable botulinum toxin type A marketed as "Innotox 100ui" and "Innotox 100u" for sale to U.S. consumers. The site made drug claims for the product, such as 89% sweat reduction for hyperhidrosis and a 78% reduction in blepharospasm episodes. FDA said no approved application is in effect for this product and its labeling lacks adequate directions for use.
What FDA found
The company offers a new drug for sale in the U.S. without an FDA-approved application.
Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]Website claims that the product treats excessive sweating and eyelid spasms show it is a drug intended for human use.
Section 201(g) of the FD&C Act [21 U.S.C. § 321(g)]; 21 CFR 201.128The product's labeling does not give adequate directions for use, so it is misbranded.
Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The product is a prescription drug and is not exempt from the adequate-directions requirement because it is unapproved.
Section 503(b) of the FD&C Act [21 U.S.C. § 353(b)]; 21 CFR 201.115(a)By offering these drugs to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.
Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 working days describing the steps taken to fix the violations and prevent them from recurring, with supporting documents. If corrections cannot be finished in that time, the company must explain why and give a completion date.
Who should pay attention
- clinics and med spas tempted to buy botulinum toxin from online sellers
- U.S. consumers buying injectables from foreign websites
- distributors and importers of Korean aesthetic injectables
This is a summary. Read the original letter on fda.gov.